ReviewCancers2023
Long-Term Non-Cancer Risks in People with
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Engineering ovarian tissue via biofabrication and 3D bioprinting: Challenges and emerging perspectives.Bioengineering & translational medicine · 2026Review
- Breaking the Cycle: A Case of Delayed Diagnosis and Sustained Remission Following Definitive Surgical Treatment of Premenstrual Dysphoric Disorder (PMDD).Case reports in psychiatry · 2026Article
- Mechanistic insights into c-Met rs368750834 mutation and a bifunctional CAR-T strategy for serous ovarian carcinoma.Journal of ovarian research · 2025Article
- Estimands for Clinical Effectiveness of Risk-Reducing Early Salpingectomy in Women With High Risk of Ovarian Cancer.JAMA network open · 2025Observational
- Long-term outcomes after unilateral salpingo-oophorectomy: A registry-based retrospective cohort study.PLoS medicine · 2025Article
- Global epidemiology of epithelial ovarian cancer.Nature reviews. Clinical oncology · 2024Review
- Primary Prevention and Early Detection of Hereditary Breast Cancer.Breast care (Basel, Switzerland) · 2023Review
- Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy inCancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Risk-reducing bilateral salpingo-oophorectomy (RRBSO) is the gold standard preventative option for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.